

Bio of Andy C. Ye

Mr. Andy C. Ye has over 15 years of demonstrated expertise in serving as a trusted advisor with an extensive network of contacts within governments, State-Owned-Enterprises, Public and Private Corporations. For the recent years, Mr. Ye has been devoted to support regenerative medicine and cancer research especially in the advanced stem cell research and commercialization area. He has also been advising business strategies, development and expansion for non-profit research institutes/foundations and for-profit corporations to achieving sustainable profit generating operations in compliance with not only local but international financial regulations.

Mr. Ye was previously a Director at Perella Weinberg Partners (<http://www.pwpartners.com>), a then \$11.5bln leading global institutional asset manager since the inception year of the asset management until the beginning of 2013. The firm is a private limited partnership with approximately 415 employees based in New York, London, Abu Dhabi, Denver, Dubai, and San Francisco. He was primarily responsible for trading for the Xerion fund which makes event-driven and special situations corporate investments across the capital structure within an overall macro-framework. Prior to joining Perella Weinberg Partners, Mr. Ye was Head Trader at Xerion Capital Partners which was launched with the backing of Paloma Partners in 2003, merging it into Perella Weinberg Partners in 2007.

Mr. Ye also held positions as a consultant and engineer at various companies and started his career at Lockheed Martin as the youngest employee selected into ELDP (Engineering Leadership Development Program) at Lockheed Martin (<http://lockheedmartin.com/>) in 2001.

Before that, Mr. Ye had worked for Mylan Pharmaceuticals and The National Institute for Occupational Safety and Health (NIOSH) of Center for Disease Control And Prevention of United States government in supporting research effort.